GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer

$581,609
David Basanta Gutierrez · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2019 · CA

Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential

$581,602
Michael Chiu · Kytopen Corp · R44 · FY2024 · AI

(7) Novel imaging devices for measurement and control of tumor microenvironments

$581,467
David Entenberg · Albert Einstein College Of Medicine · R01 · FY2021 · CA

Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer

$581,465
Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2023 · CA

Aerosol Delivery of Topotecan for Personalized Lung Cancer Therapy

$581,451
Mathewos Tessema · Lovelace Biomedical & Environmental Research Institute · R01 · FY2018 · CA

Targeting Stromal Influences on BCKA Addiction in PDAC Tumors

$581,396
Deepak Nagrath · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Effects of chronic pubertal stressors on mammary gland biology and cancer risk

$581,368
Matthew J Brady · University Of Chicago · R01 · FY2020 · CA

Lymphocyte signaling and immune cell response

$581,362
Tasha Morrison · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2025 · AR

Intravital Microscopy Core

$581,355
Roberto Weigert · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA

Credentialing Mouse Models for Immune System Therapy Research

$581,304
Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA

Credentialing Mouse Models for Immune System Therapy Research

$581,304
Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA

Simultaneous Microwave and MR Imaging for Improved Diagnosis of Breast Abnormalities

$581,228
Keith D. Paulsen · Dartmouth College · R01 · FY2022 · CA

An integrated microtechnology platform for spatially resolved mass spectrometry-based proteomics

$581,119
Sindy Kam-Yan Tang · Stanford University · R01 · FY2024 · CA

Genetically-engineered Bacteria Overcome Therapy Resistance

$581,087
Ralph R Weichselbaum · University Of Chicago · R01 · FY2024 · CA

Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment

$581,057
Kathryn Miller-Jensen · Yale University · U01 · FY2020 · CA

Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial

$581,039
Lei Zheng · Johns Hopkins University · R01 · FY2021 · CA

VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy

$580,985
Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma

$580,946
Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · CA

Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

$580,914
Farrokh Dehdashti · Washington University · R01 · FY2020 · CA

Structure-informed dissection of cancer-specific intracellular and paracrine networks

$580,864
Barry H Honig · Columbia University Health Sciences · U54 · FY2023 · CA

A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)

$580,861
Jenny C-N Chang · Methodist Hospital Research Institute · U01 · FY2024 · CA

Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity

$580,676
Maria Virginia Pascual · Weill Medical Coll Of Cornell Univ · U19 · FY2021 · AI

Understanding IDH mutant gliomas

$580,621
Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Development of Angiogenesis Inhibitors

$580,614
William Douglas Figg · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA

The linkage between Race, Kaiso and the tumor microenvironment in breast cancer health disparities

$580,326
Kevin L. Gardner · Columbia University Health Sciences · R01 · FY2022 · CA